Emerging role of calprotectin in gastroenterology

Poullis, Andrew; Foster, Russell G.; Mendall, Michael A.; Fagerhol, Magne K.

doi:10.1046/j.1440-1746.2003.03014.x

Cited by 102 publications

(85 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, fecal calprotectin can only refl ect the excretion of neutrophils. Many infective diseases can cause a large number of neutrophils to infiltrate, so that fecal calprotectin is elevated in a number of organic gastroenterological disorders [29][30][31] . Therefore, fecal calprotectin is not desirable as a method that is required to differentiate efficiently between UC and infective colitis, so it cannot take the place of an endoscope in diagnosing UC.…”

Section: Discussionmentioning

confidence: 99%

Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis

Xiang¹,

Ouyang²,

Li³

et al. 2008

WJG

101

View full text Add to dashboard Cite

AIM:To investigate possibility and clinical application of fecal calprotectin in determining disease activity of ulcerative colitis (UC). METHODS:The enzyme-linked immunosorbent assay (ELISA) was used to measure the concentrations of calprotectin in feces obtained from 66 patients with UC and 20 controls. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), acid glycoprotein (AGP) were also measured and were compared with calprotectin in determining disease activity of UC. The disease activity of UC was also determined by the Sutherland criteria. RESULTS:The fecal calprotectin concentration in the patients with active UC was signifi cantly higher than that in the inactive UC and in the controls (402.16 ± 48.0 μg/g vs 35.93 ± 3.39 μg/g, 11.5 ± 3.42 μg/g, P < 0.01).The fecal calprotectin concentration in the inactive UC group was signifi cantly higher than that in the control group (P < 0.05). A signifi cant difference was also found in the patients with active UC of mild, moderate and severe degrees. The area under the curve of the receiver operating characteristics (AUC ROC ) was 0.975, 0.740, 0.692 and 0.737 for fecal calprotectin, CRP, ESR and AGP, respectively. There was a strong correlation between the fecal calprotectin concentration and the endoscopic gradings for UC (r = 0.866, P < 0.001). CONCLUSION:Calprotectin in the patient's feces can refl ect the disease activity of UC and can be used as a rational fecal marker for intestinal infl ammation in clinical practice. This kind of marker is relatively precise, simple and noninvasive when compared with other commonlyused markers such as CRP, ESR and AGP.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis

Xiang¹,

Ouyang²,

Li³

et al. 2008

WJG

101

View full text Add to dashboard Cite

show abstract

“…S100A8 was another biomarker identified in the Apc Minϩ/Ϫ mouse adenomas, and we further confirmed that its expression increases as human CRC progresses from normal to higher stages (Duke's stages A-D) at both the protein and RNA levels in two relatively large human CRC sample sets. S100A8 binds with calgranulin B to form a complex called calprotectin (43). As a calcium-and zinc-binding protein, calprotectin is a multipotent molecule and can inhibit several zinc-dependent metalloproteinases by sequestration of zinc (44).…”

Section: Discussionmentioning

confidence: 99%

Identification of Early Intestinal Neoplasia Protein Biomarkers Using Laser Capture Microdissection and MALDI MS

Xu¹,

Beauchamp

et al. 2009

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Obtaining protein profiles from a homogeneous cell population in tissues can significantly improve our capability in protein biomarker discovery. In this study, unique protein profiles from the top and bottom sections of mouse crypts and Apc Min؉/؊ adenomas were obtained using laser capture microdissection (LCM) combined with MALDI MS. Statistically significant protein peaks with differential expression were selected, and a set of novel protein biomarkers were identified. Immunohistochemistry was performed to confirm the differentially expressed protein biomarkers found by LCM combined with MALDI MS. To validate the relevance of the findings in human colorectal cancer (CRC), S100A8 was further confirmed in human CRC using immunohistochemistry. In addition, S100A8 was found to have an increased expression at different human CRC stages (Duke's A-D) compared with controls at both protein (n ‫؍‬ 168 cases) and RNA (n ‫؍‬ 215 cases) levels. Overall LCM combined with MALDI MS is a promising method to identify intestinal protein biomarkers from minute amounts of tissue. The novel protein biomarkers identified from the top and bottom crypts will increase our knowledge of the specific protein changes taking place during cell migration from the crypt bottom to top. In addition, the identified cancer protein biomarkers will aid in the exploration of colorectal tumorigenesis mechanisms as well as in the advancement of molecularly based diagnosis of colorectal cancer. Molecular & Cellular Proteomics 8:936 -945, 2009.

show abstract

“…Moreover, increased levels of fecal calprotectin have been reported in patients with several other inflammatory conditions of the lower gastrointestinal tract and even in patients affected by neoplastic disease of both upper and lower gastrointestinal tract (Brydon et al, 2001;Poullis et al, 2003). Therefore, measuring fecal calprotectin has been proposed as useful noninvasive diagnostic tool for differentiating patients with organic disease of the intestinal tract from those with functional diseases.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of Fecal Calprotectin as a Screening Biomarker for Gastrointestinal Malignancies

Khoshbaten¹,

Pishahang²,

Nouri³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Calprotectin in feces seems to be a more sensitive marker for gastrointestinal (GI) cancers than fecal occult blood, but its specificity may be too low for screening average risk populations. This study aims at evaluating the diagnostic value of fecal calprotectin as a screening biomarker for GI malignancies. Materials and Methods: In a case-control study, 100 patients with GI malignancies (50 patients with colorectal cancer and 50 patients with gastric cancer) and 50 controls were recruited in Tabriz 3) in gastric cancer, colorectal cancer and control group, respectively, the differences being significant (p<0.001) and remaining after adjustment for age. The optimal cut-off point for fecal calprotectin was ≥75.8µg/g for distinguishing colorectal cancer from normal cases (sensitivity and specificity of 80% and 84%, respectively). This value was ≥41.9µg/g for distinguishing gastric cancer from normal cases (sensitivity and specificity of 62%). Conclusions: Our results revealed that fecal calprotectin might be a useful and non-invasive biomarker for distinguishing colorectal cancer from non-malignant GI conditions. However, due to low sensitivity and specificity, this biomarker may not help physicians distinguishing gastric cancer cases from healthy subjects.

show abstract

Emerging role of calprotectin in gastroenterology

Cited by 102 publications

References 60 publications

Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis

Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis

Identification of Early Intestinal Neoplasia Protein Biomarkers Using Laser Capture Microdissection and MALDI MS

Diagnostic Value of Fecal Calprotectin as a Screening Biomarker for Gastrointestinal Malignancies

Contact Info

Product

Resources

About